HealthDay on MSN1d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPDFor patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...
MedPage Today on MSN7d
Have the New Pulmonary Hypertension Drugs Changed the Game?After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...
MedPage Today on MSN2d
What's With All the UFH Infusions for Acute Pulmonary Embolism?Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...
Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the ...
China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...
Delamanid is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Pulmonary Tuberculosis.
The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...
A noninvasive approach could help clinicians prescribe medications more precisely for patients according to endotype.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback